FFO
NMRA icon

Fortitude Family Office’s Neumora Therapeutics NMRA Stock Holding History

Fortitude Family Office’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-167
Closed -$326 – 2342
2026
Q1 		$326 Sell
167
-855
-84% -$2.22K ﹤0.01% 1818
2025
Q4 		$1.83K Hold
1,022
– – ﹤0.01% 1214
2025
Q3 		$1.86K Buy
+1,022
New +$1.65K ﹤0.01% 1257

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellcome Trust
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Iconiq Capital
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fortitude Family Office's NMRA Position: Q2 2026 in Review

Fortitude Family Office sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 167 shares — an estimated $326 sold.

Fortitude Family Office first reported a position in NMRA in Q3 2025 and held it in 3 quarters. The position peaked at $1.86K in Q3 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Fortitude Family Office reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 167 Neumora Therapeutics shares in Q2 2026, an estimated $326.
  • Fortitude Family Office first reported a position in Neumora Therapeutics in Q3 2025 and held it in 3 quarters.
  • Fortitude Family Office's Neumora Therapeutics position peaked at $1.86K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.